- Country: Argentina
- Summary: Linezolid and Daptomycin and Vs. Pctes.rocha, Leon Alarcon and Tejerina-pharmacy
- ART Ref No: 101504476
- Deadline: 24 May 2024
- Financier: Self Financed
- Purchaser Ownership: Government
- Tender Value: ARS 14326400.00
- Notice Type: Tender
- Document Ref. No.: 430-0919-CDI24
- Purchaser's Detail:Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
- Description:
- Linezolid. Model: 600 mg, solution for infusion with 600 mg/300 ml, in Sachet, Daptomycin. Model: 500 mg, injectable, lyophilized, in blister + solvent x 10 ml, intravenous use, riluzol. Model: 50 mg, in covered tablet, dextrometorfano brumhydrate + sulfate quinidine Other specifications should be indicated by the requesting distribution model: dextrometorfano Bromhydrate 20 mg + Quinidine sulfate 10 mg, in caps See more, citheate magnesium. Model: 528 mg, in dragea, mycophenolate. Model: 360 mg (as sodium salt), in tablet
- Documents:
If you are registered member, kindly login to view full details of this tender notice:
CLICK HERE TO LOGINLinezolid and Daptomycin and Vs. Pctes.rocha, Leon Alarcon and Tejerina-pharmacy - Argentina Tender
The HTAL. JOSE M. WE MEJIA, a Government sector organization in Argentina, has announced a new tender for Linezolid and Daptomycin and Vs. Pctes.rocha, Leon Alarcon and Tejerina-pharmacy. This tender is published on ArgentinaTenders under ART Ref No: 101504476 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2024-05-24.
The estimated tender value is ARS 14326400.00, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.
